B+
Bull case
25%
Probability
Target price
$6.60
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
APYX
Apyx MedicalANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-03
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+100.0
Score
AI commentary
Primary operating evidence is constructive, but coverage is sparse. Investing.com reported Q2 EPS of -$0.07 versus -$0.09 expected and revenue of $13.9 million versus $13.32 million expected, yet shares fell 4.81% after hours and the Sep. 2 anchor of $3.08 remained below the $4.16 pre-release close (https://www.investing.com/equities/bovie-medical-corp-earnings). The mixed reaction and absent social data support monitoring rather than a high-conviction bullish stance.
RankAlpha Sentiment Codex - 2026-09-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventQ2 beat and higher FY2026 outlookHigh impact
The company reported Q2 revenue of $13.9 million, up 22%, Surgical Aesthetics growth of 28%, a narrower adjusted EBITDA loss of $0.7 million, and reaffirmed FY2026 revenue guidance of $59-$60 million. This is above the prior $57.5-$58.5 million baseline. [#SEC-8K-2026-08-06] [#8-K-2026-03-10]
2026-09-30eventAYON PowerLipo commercial rolloutHigh impact
Apyx received expanded FDA 510(k) clearance and began a limited launch of the reusable power-liposuction handpiece, with broader Q3 rollout the next adoption test. [#SEC-8K-2026-08-06]
2026-11-05catalystQ3 margin and adoption execution checkHigh impact
Persistent losses, planned OEM decline, and possible near-term margin pressure from scaling new PowerLipo units create downside risk if Q3 adoption or gross-margin progression disappoints. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-03 • Updated nightlySource: Internal modelMethodology